drugset / Trial / NCT00554385

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00554385

Phase 2 Terminated 283 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in children with ADHD.

Timeline

Start
2007-11
Primary completion
2008-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Pozanicline Small molecule 1 mg
Subject Pozanicline Small molecule 5 mg
Subject Pozanicline Small molecule 10 mg
Subject Pozanicline Small molecule 40 mg
Subject Pozanicline Small molecule 80 mg